- KINASE ANTAGONISTS AND METHODS FOR MAKING AND USING THEM
-
Disclosed herein are small molecule compounds that are SGK1 antagonists, formulations and pharmaceutical compositions comprising the compounds, and methods of making and using them, for treating, ameliorating, preventing, reversing or slowing the progression of: a cancer, a tumor, a metastasis or a dysplastic or a dysfunctional cell condition responsive to inhibition of a kinase enzyme of the AGC group of kinases including SGK1, by administration of an AGC kinase inhibitor or antagonist.
- -
-
Page/Page column 132-134
(2020/02/19)
-
- SUBSTITUTED OXAZOLIDINONES FOR THE TREATMENT OF MAMMALIAN INFECTIONS
-
Present invention relates to novel compound of formula (I), their enantiomers, their diastereomers, their pharmaceutically accepted salts, or pro-drugs thereof, which are useful for the treatment of bacterial infection.
- -
-
Page/Page column 14
(2020/02/16)
-
- NOVEL DUAL MODE OF ACTION SOLUBLE GUANYLATE CYCLASE ACTIVATORS AND PHOSPHODIESTERASE INHIBITORS AND USES THEREOF
-
The present invention relates to compounds of formula I or pharmaceutically acceptable salt, solvate or hydrate thereof and their use in methods of treating or preventing a disease alleviated by inhibition of PDE5 in a human or in a non-human mammal.
- -
-
Page/Page column 121-122
(2018/12/13)
-
- SOLID SUPPORTS AND PHOSPHORAMIDITE BUILDING BLOCKS FOR OLIGONUCLEOTIDE CONJUGATES
-
Novel non-nucleoside solid supports and phosphoramidite building blocks for preparation of synthetic oligonucleotides containing at least one non-nucleosidic moiety conjugated to a ligand of practical interest and synthetic processes for making the same are disclosed. Furthermore, oligomeric compounds are prepared using said solid supports and phosphoramidite building blocks, preferably followed by removal of protecting groups to provide oligonucleotides conjugated to ligands of interest.
- -
-
Paragraph 0164-0165
(2018/02/14)
-
- Having a spiro ring substituent of aryl morpholine compound, its preparation and use
-
The invention discloses arylmorpholine compounds with spiro substituents. The arylmorpholine compounds are compounds having the following general formula (I), wherein X is N or CH; R1 is hydrogen, hydroxyl, alkoxy, halogen, amino, amido, acylamino, sulfam
- -
-
Paragraph 0202; 0203; 0207
(2017/08/02)
-
- MTH1 INHIBITORS FOR TREATING DISEASE
-
Disclosed herein are compounds and compositions having the structure of Formula I, which are useful in the treatment of diseases, such as cancer, where inhibition of MTHl is expected to confer an advantage to a patient. Methods of inhibition of MTHl activity in a human or animal subject are also provided.
- -
-
Paragraph 0186
(2016/09/26)
-
- An improved synthesis of 2-oxa-7-azaspiro[3,5]nonane and analogs as novel reagents in medicinal chemistry
-
A detailed synthesis of novel spirocyclic oxetane analogs is described for the first time.
- Xu, Ruo,Czarniecki, Michael,Man, Jos De,Pan, Jianping,Qiang, Li,Root, Yuriko,Ying, Shihong,Su, Jing,Sun, Xijun,Zhang, Yuping,Yu, Tao,Zhang, Yang,Hu, Tao,Chen, Shu-Hui
-
experimental part
p. 3266 - 3270
(2011/07/08)
-
- PHOSPHORUS DERIVATIVES AS HISTONE DEACETYLASE INHIBITORS
-
The present invention relates to a novel class of phosphorus derivatives. The phosphorus compounds can be used to treat cancer. The phosphorus compounds can also inhibit histone deacetylase and are suitable for use in selectively inducing terminal differe
- -
-
Page/Page column 135
(2008/06/13)
-
- QUINOLONE ANTIBACTERIAL AGENTS
-
Compounds of formula (I, II, III, IV, V, and VI) and methods for their preparation are disclosed. Further disclosed are methods of making biologically active compounds of formula (I) as well as pharmaceutically acceptable compositions comprising compounds of formula (I). Compounds of formula (I) as disclosed herein can be used in a variety of applications including use as antibacterial agents.
- -
-
Page/Page column 114; 115
(2010/02/11)
-
- Cyclohexane derivatives and their use as therapeutic agents
-
The present invention relates compounds of formula (I), wherein ring A is a phenyl or pyridyl ring; X represents a linker selected from the group consisting of formulae: (a), (b), (c), (d), and (e); and R1, R2, R3, R4, R5, R6, R7, R13, R14, R15, R16, R17, R21a and R21b are as defined herein. The compounds are of particular use in the treatment or prevention of depression, anxiety, pain, inflammation, migraine, emesis or postherpetic neuralgia.
- -
-
-